Hikma Pharmaceuticals Plc Director/PDMR Shareholding (0062L)
01 9월 2023 - 3:06AM
UK Regulatory
TIDMHIK
RNS Number : 0062L
Hikma Pharmaceuticals Plc
31 August 2023
Hikma Pharmaceuticals PLC - LTIP Award
LONDON, 31 August 2023: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the
Remuneration Committee made the following conditional award under
the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the
"LTIP") to Riad Mishlawi, a Person Discharging Managerial
Responsibility ("PDMR") of the Company. No consideration was paid
for the grant of the award.
The award under the LTIP was made on 31 August 2023 based on a
price of GBP21 per Ordinary Share (being the average mid-market
Ordinary Share price for the for the 5-working day period prior to
31 August 2023, in accordance with the LTIP rules) (the "LTIP
Award"). This LTIP Award reflects Riad Mishlawi's promotion to
Chief Executive Officer of Hikma Pharmaceuticals PLC, effective 1
September 2023 and has been made on a pro-rata basis, taking
account of his LTIP Award granted on 30 May 2023. The vesting of
the LTIP Award is subject to the continued employment of the PDMR,
malus and clawback provisions and the satisfaction of performance
conditions set by the Remuneration Committee of the Company. The
LTIP Award will normally vest on the later of the third anniversary
of the date of grant and the determination of the performance
conditions. The LTIP Award is then subject to an additional
two-year holding period.
This notification is made under Article 19(1) of the EU Market
Abuse Regulation 596/2014 as it forms part of domestic law by
virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The
information set out below is provided in accordance with the
requirements of Article 19(3) of MAR.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Grant of award under the LTIP.
transaction
c) Price(s) and Price(s) Volume(s)
volume(s)
Nil LTIP Award: 12,623 Shares
d) Aggregated information Price(s): nil
Volume(s): 12,263
e) Date of the transaction 31 August 2023
f) Place of the Outside a trading venue
transaction
Helen Middlemist
Deputy Company Secretary
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUGDIDBXDGXB
(END) Dow Jones Newswires
August 31, 2023 11:14 ET (15:14 GMT)
Hikma Pharmaceuticals (LSE:HIK)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Hikma Pharmaceuticals (LSE:HIK)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024